middle.news
NeuroScientific Advances StemSmart Clinical Program and Manufacturing Scale-Up
9:38am on Thursday 30th of April, 2026 AEST
•
Biotechnology
Read Story
NeuroScientific Advances StemSmart Clinical Program and Manufacturing Scale-Up
9:38am on Thursday 30th of April, 2026 AEST
Key Points
Positive clinical responses in 3 of 4 Crohn’s patients
Manufacturing transfer to Q-Gen Cell Therapeutics underway
FDA pre-IND engagement shaping Phase 2 trial design
EmtinB™ glaucoma program faces technical and timeline challenges
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuroscientific Biopharmaceuticals (ASX:NSB)
OPEN ARTICLE